Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.
Expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) is associated with poor glioblastoma outcomes.
Pregnancy might stimulate tumor growth among women diagnosed with gliomas, according to a single-institution retrospective review of cases.
Targeted MAPK-pathway inhibitor therapies appear to have reduced tumor sizes in four children’s inoperable astrocytomas—tumors that had progressed despite chemotherapy.
HLA-A2-positive glioblastoma patients experienced more frequent immune responses to the dendritic-cell immunotherapy IDT-107, responses that may be associated with improved survival.
Adding adjuvant gene-mediated cytotoxic immunotherapy using aglatimagene besadenovec and valacyclovir to standard of care improves survival among patients undergoing surgery for newly diagnosed malignant glioma.
Adding rindopepimut to bevacizumab therapy was associated with improved long-term survival in patients with recurrent EGFRvIII-positive glioblastoma.
Serum matrix metalloproteinase 9 (MMP-9) and HER2 extra-cellular domain (HER2-ECD) might be predictive biomarkers for the metastasis of breast cancer to the brain, according to a case-control study.
Adding procarbazine, CCNU, and vincristine to radiotherapy offers pronounced survival benefits for patients with low-grade gliomas harboring IDH1 R132H mutations.
Despite promising progression-free survival results, the combination of bevacizumab and lomustine for the treatment of first recurrence in glioblastoma did not improve overall survival, according to findings from the phase III EORTC-26101 trial.